Literature DB >> 20119493

Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients.

Steven B Zeliadt1, Scott D Ramsey, Arnold L Potosky, Neeraj K Arora, David K Blough, Ingrid Oakley-Girvan, Ann S Hamilton, Stephen K Van Den Eeden, David F Penson.   

Abstract

BACKGROUND: The choice between surgical versus non-surgical treatment options is a fundamental decision for men with local stage prostate cancer because of differences in risks of genitourinary side effects among available treatments.
OBJECTIVES: We assessed whether preexisting genitourinary symptoms at the time of diagnosis influenced men's preferences for surgery versus other management options.
METHODS: We recruited 593 patients with newly diagnosed local stage prostate cancer prior to initiating treatment from an integrated health care system, an academic urology center, and community urology clinics. Using logistic regression we compared whether men had a preference for non-surgical options or only preferred surgery.
RESULTS: Nearly 60% indicated they were considering non-surgical options. Age and clinical characteristics but not preexisting genitourinary symptoms influenced the decision between preferences for surgical or non-surgical options. A total of 62% of men reported side effects as a main factor in their treatment decision. Men with more aggressive tumor types were less likely to consider side effects, however, men who reported poor ability to have an erection were more likely to consider side effects (p<0.001).
CONCLUSION: Sexual dysfunction at time of diagnosis, but not other genitourinary symptoms, is associated with men considering treatment-related side effects when considering surgery versus other options. Men who are not experiencing sexual dysfunction at diagnosis may discount the risks of side effects in the decision making process.

Entities:  

Year:  2008        PMID: 20119493      PMCID: PMC2812903          DOI: 10.2165/1312067-200801030-00006

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  31 in total

1.  Evaluation of a question-and-answer booklet on early-stage prostate-cancer.

Authors:  Deb Feldman-Stewart; Michael D Brundage; Lori Van Manen; David Skarsgard; Rob Siemens
Journal:  Patient Educ Couns       Date:  2003-02

2.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer.

Authors:  Willie Underwood; Sonya De Monner; Peter Ubel; Angela Fagerlin; Martin G Sanda; John T Wei
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

3.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

4.  Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

Authors:  Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

5.  Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study.

Authors:  J Legler; A L Potosky; F D Gilliland; J W Eley; J L Stanford
Journal:  Med Care       Date:  2000-08       Impact factor: 2.983

6.  Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor.

Authors:  M S Litwin; S C Flanders; D J Pasta; M L Stoddard; D P Lubeck; J M Henning
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

7.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

8.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

9.  Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE.

Authors:  Shilpa S Mehta; Deborah P Lubeck; David J Pasta; Mark S Litwin
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

10.  Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina.

Authors:  W Demark-Wahnefried; J M Schildkraut; C E Iselin; E Conlisk; A Kavee; T E Aldrich; E J Lengerich; P J Walther; D F Paulson
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

View more
  3 in total

1.  Complementary and alternative medicine use among newly diagnosed prostate cancer patients.

Authors:  Cara L McDermott; David K Blough; Catherine R Fedorenko; Neeraj K Arora; Steven B Zeliadt; Megan E Fairweather; Ingrid Oakley-Girvan; Stephen K Van Den Eeden; Scott D Ramsey
Journal:  Support Care Cancer       Date:  2010-12-01       Impact factor: 3.603

2.  Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer.

Authors:  Scott D Ramsey; Steven B Zeliadt; David K Blough; Catherine R Fedorenko; Megan E Fairweather; Cara L McDermott; David F Penson; Stephen K Van Den Eeden; Ann S Hamilton; Neeraj K Arora
Journal:  Urology       Date:  2012-05       Impact factor: 2.649

Review 3.  Factors that influence patient preferences for prostate cancer management options: A systematic review.

Authors:  Timothy N Showalter; Mark V Mishra; John Fp Bridges
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.